The FDA found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent, including discovery of a 'pest' on the manufacturing line.
The plant will create more than 150 new highly skilled jobs to focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world.